Primary hyperparathyroidism and the skeleton (Q37048218)

17 August 2017

1 reference

title

Primary hyperparathyroidism and the skeleton (English)

1 reference

primary hyperparathyroidism

17 August 2017

1 reference

1 reference

Leif Mosekilde

1 reference

17 August 2017

publication date

1 July 2008

1 reference

17 August 2017

published in

Clinical Endocrinology

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

1-19

1 reference

Primary hyperparathyroidism: changes in the pattern of clinical presentation

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Update on genetic and clinical aspects of primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

RANKL-RANK signaling in osteoclastogenesis and bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment--evaluated by histomorphometric methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Anabolic actions of parathyroid hormone on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Bone measurements in asymptomatic primary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Primary hyperparathyroidism: whole-body bone mineral density in surgically treated Danish patients: a three-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Recovery of bone mineral density in 126 patients after surgery for primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The effects of vitamin D insufficiency in patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Continuing bone growth throughout life: A general phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Consequences of the remodelling process for vertebral trabecular bone structure: a scanning electron microscopy study (uncoupling of unloaded structures).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Minireview: vitamin D receptor: new assignments for an already busy receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Calcium and 1,25(OH)2D: interacting drivers of epidermal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Influence of renal function on clinico-pathological features of primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The effects of smoking on bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Smoking and hormones in health and endocrine disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Relationships between intestinal calcium absorption, serum vitamin D metabolites and smoking in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Current pharmacological options for the management of primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Calcimimetics and the treatment of primary and secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Mouse osteoblastic cell line (MC3T3-E1) expresses extracellular calcium (Ca2+o)-sensing receptor and its agonists stimulate chemotaxis and proliferation of MC3T3-E1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2007.03162.X

10.1111/J.1365-2265.2007.03162.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference